News
EGRX
35.25
-1.23%
-0.44
Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel
-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s ho...
GlobeNewswire · 11/16 11:50
BRIEF-Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug For The Treatment Of Pneumonia
Reuters · 11/14 12:03
Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug Application For CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent For The Adjunct Treatment Of Severe Community-Acquired Bacterial Pneumonia
Benzinga · 11/14 11:51
Eagle Pharmaceuticals Says FDA Accepts Investigational New Drug Application for CAL02 to Treat Pneumonia
Eagle Pharmaceuticals Says FDA Accepts Investigational New Drug Application for CAL02 to Treat Pneumonia
MT Newswires · 11/14 10:53
Industry Analysts Just Made A Substantial Upgrade To Their Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Revenue Forecasts
Shareholders in Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) may be thrilled to learn that the analysts have just...
Simply Wall St. · 11/09 10:22
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Reports Q3 Revenue $65.9M, vs. Street Est of $66.7M
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Reports Q3 Revenue $65.9M, vs. Street Est of $66.7M
MT Newswires · 11/09 07:07
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08 10:00
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
Benzinga · 11/08 07:00
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 11/07 18:28
ACMR, ARQQ and NXTC among mid-day movers
Seekingalpha · 11/07 18:16
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Benzinga · 11/07 17:46
--Cantor Fitzgerald Adjusts Eagle Pharmaceuticals Price Target to $37 From $45, Maintains Neutral Rating
--Cantor Fitzgerald Adjusts Eagle Pharmaceuticals Price Target to $37 From $45, Maintains Neutral Rating
MT Newswires · 11/07 14:10
Recap: Eagle Pharmaceuticals Q3 Earnings
Benzinga · 11/07 12:15
Eagle Pharmaceuticals Non-GAAP EPS of $1.12 beats by $0.21, revenue of $65.9M beats by $3.82M
Seekingalpha · 11/07 11:56
BRIEF-Eagle Pharmaceuticals Reports Third Quarter 2022 Results
Reuters · 11/07 11:53
Eagle Pharmaceuticals Q3 Adj. EPS $1.12 Beats $0.91 Estimate, Sales $65.90M Beat $62.08M Estimate
Benzinga · 11/07 11:52
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Posts Q3 EPS $1.12, vs. Street Est of $0.91
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Posts Q3 EPS $1.12, vs. Street Est of $0.91
MT Newswires · 11/07 07:04
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Reports Q3 Revenue $65.9M, vs. Street Est of $62.1M
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Reports Q3 Revenue $65.9M, vs. Street Est of $62.1M
MT Newswires · 11/07 06:56
Eagle Pharmaceuticals Q3 2022 Earnings Preview
Seekingalpha · 11/04 17:25
Notable earnings before Monday's open
Seekingalpha · 11/04 14:26
More
Webull provides a variety of real-time EGRX stock news. You can receive the latest news about Eagle Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About EGRX
Eagle Pharmaceuticals, Inc. is a pharmaceutical company. The Company's products include Ryanodex, Bendeka, Belrapzo, Treakisym, Pemfexy, Barhemsys and Byfavo. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.